Maravai LifeSciences Reports Steep Revenue Decline, Negative EBITDA, Major Impairments, and 25% Workforce Cut in Challenging 2025 Annual Report
MRVI has more than doubled off its 52-week low of $1.665 on elevated volume (3.3× avg).
Summary
Maravai LifeSciences reported a significant decline in 2025 revenue and gross profit, a shift to negative Adjusted EBITDA and operating cash flow, and recorded substantial asset impairments, leading to a 25% workforce reduction and derecognition of its Tax Receivable Agreement liability due to a pessimistic outlook on future taxable income.
Key Events · Earnings and Guidance · MRVI
-
Significant Revenue and Profit Decline
Total revenue decreased by 28.3% to $185.7 million in 2025 from $259.2 million in 2024. Gross profit fell by 68.6% to $34.0 million, with the gross profit margin dropping from 41.8% to 18.3%, primarily due to the absence of high-volume CleanCap sales for commercial phase vaccine programs.
-
Shift to Negative Adjusted EBITDA and Operating Cash Flow
The company reported a negative Adjusted EBITDA of $(31.2) million in 2025, a significant decline from $35.9 million in 2024. Net cash used in operating activities was $(57.6) million, compared to $7.5 million provided in the prior year, indicating a worsening cash burn from core operations.
-
Major Goodwill and Intangible Asset Impairments
Maravai recorded $68.7 million in goodwill and intangible asset impairments in 2025, reflecting lower projected revenues and demand in its TriLink BioTechnologies and Alphazyme reporting units.
-
Workforce Reduction and Cost Realignment Plan
The company implemented a 2025 Corporate Realignment Plan, including the termination of approximately 25% of its workforce and a phased reduction of its facilities footprint, aiming for over $65.0 million in annualized cost savings.
Analysis · MRVI · Life Sciences
Maravai LifeSciences' 2025 annual report reveals a challenging year marked by significant financial deterioration. The substantial decline in revenue and gross profit, coupled with a shift to negative Adjusted EBITDA and operating cash flow, indicates severe business headwinds, particularly from the absence of high-volume vaccine-related sales. The large goodwill and intangible asset impairments further underscore a reassessment of asset values and future prospects. The 25% workforce reduction and facility streamlining, while aimed at cost savings, highlight the depth of the operational challenges. The derecognition of the Tax Receivable Agreement liability is a strong signal of a pessimistic outlook on future taxable income. However, the company has taken positive steps by appointing new executive leadership, successfully remediating material weaknesses in internal controls, and resolving a securities class action lawsuit, which may provide a foundation for future recovery.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRVI was trading at $3.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $910.3M. The 52-week trading range was $1.67 to $4.11. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.